Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4695552 | 0.83 | SMN1; SMN2 (0.50) | BCHECHRM3SMN1; SMN2CHRM4CHRM5 | |
| SCHEMBL26442750 | 0.79 | SMN1; SMN2 (0.50) | BCHECHRM3SMN1; SMN2CHRM4CHRM5 | |
| SCHEMBL25856259 | 0.78 | — | — | |
| SCHEMBL18633797 | 0.78 | SMN1; SMN2 (0.48) | BCHECHRM3SMN1; SMN2CHRM4CHRM5 | |
| SCHEMBL27675066 | 0.78 | SMN1; SMN2 (0.58) | BCHECHRM3SMN1; SMN2CHRM4CHRM5 | |
| Hydrochloric Acid SCHEMBL2945460 | 0.78 | SMN1; SMN2 (0.48) | BCHECHRM3SMN1; SMN2CHRM4CHRM5 | |
| SCHEMBL16845009 | 0.76 | SMN1; SMN2 (0.47) | BCHECHRM3SMN1; SMN2CHRM4CHRM5 | |
| SCHEMBL8258790 | 0.75 | ATM (0.41) | BCHECHRM3CHRM4CHRM5CHRM1 | |
| SCHEMBL14759201 | 0.74 | EPHX1 (0.44) | BCHECHRM3CHRM4CHRM5CHRM1 | |
| SCHEMBL12292879 | 0.74 | EPHX1 (0.39) | BCHECHRM3CHRM4CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329752-B2 | Carbamate compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-20070117796-A1 | Carbamate compounds as 5-HT4 receptor agonists | THERAVANCE, INC. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117796-A1 | Carbamate compounds as 5-HT4 receptor agonists | HTR4, HTR1A, HTR2B | BCHE 863/4885CHRM3 72/4885SMN1; SMN2 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.